Minerva Neurosciences (NERV) Current Deferred Revenue (2014 - 2016)
Minerva Neurosciences posted quarterly Current Deferred Revenue of $3.5 million for Q3 2016, up 42801.4% on a QoQ basis from $8237.0 in Q1 2015.
Minerva Neurosciences (NERV) has 3 years of Current Deferred Revenue data on file, last reported at $3.5 million in Q3 2016.
- For the quarter ending Q3 2016, Current Deferred Revenue changed N/A year-over-year to $3.5 million; the trailing twelve-month figure through Sep 2016 stood at $3.5 million (changed N/A YoY), and the FY2014 full-year result was $7226.0, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2016 stood at $3.5 million, up from $8237.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.5 million in Q3 2016 and bottomed at $7226.0 in Q4 2014.
- The 3-year median for Current Deferred Revenue is $8237.0 (2015), against an average of $1.2 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 3.53 Mn |
| Mar 31, 2015 | 8,237.00 |
| Dec 31, 2014 | 7,226.00 |